February 2, 2015

Contact:
Corporate Communications,
Astellas Pharma Inc.
TEL +81-3-3244-3201

Financial Results of Astellas for the First Nine Months of FY2014 (IFRS)

Japan, February 2, 2015 – Astellas Pharma Inc. (hereinafter referred to as "the Company") today announced the financial results for the first nine months of the fiscal year 2014 (FY2014) ending March 31, 2015.

Consolidated financial results for the first nine months of FY2014 (April 1, 2014 – December 31, 2014) (core basis)

(Millions of yen)

	First nine months of FY2013	**First nine months of FY2014**	Change (%)
Sales	868,263	**952,772**	+84,509 (+9.7%)
Core operating profit	160,581	**200,193**	+39,613 (+24.7%)
Core profit for the period	112,583	**140,285**	+27,701 (+24.6%)
Core earnings per share (yen)	50.00	**63.42**	+13.42 (+26.8%)

Cautionary statement regarding forward-looking information

This press release includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Consequently, any statements herein do not constitute assurances regarding actual results by the Company. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the Company to market existing and new products effectively, interruptions in production, infringements of the Company's intellectual property rights and the adverse outcome of material litigation.

1. Qualitative information on consolidated financial results for the first nine months of FY2014

(1) Information on business performance

<Consolidated financial results (core basis)>

The Company discloses financial results on a core basis as an indicator of its recurring profitability. Certain items reported in financial results on a full basis that are deemed to be non-recurring items by the Company are excluded as non-core items from these financial results on a core basis. These adjusted items include impairment losses, gain/loss on sales of property, plant and equipment, restructuring costs, loss on disaster, a large amount of losses on compensation or settlement of litigations and other legal disputes, and other items that the Company judges should be excluded. A reconciliation table between results on a full basis and results on a core basis is provided on page 21 of the "Supplement Documents for Results 3Q/FY2014."

Consolidated financial results (core basis) in the first nine months of FY2014 showed increases in sales, core operating profit and core profit for the period, as follows.

Consolidated financial results (core basis)

(Millions of yen)

	First nine months of FY2013	**First nine months of FY2014**	Change (%)
Sales	868,263	**952,772**	+84,509 (+9.7%)
Core operating profit	160,581	**200,193**	+39,613 (+24.7%)
Core profit for the period	112,583	**140,285**	+27,701 (+24.6%)
Core earnings per share (yen)	50.00	**63.42**	+13.42 (+26.8%)

(Note) The Company conducted a stock split of common stock at a ratio of 5 for 1 with an effective date of April 1, 2014. Core earnings per share is calculated based on the number of issued shares after the stock split (excluding treasury shares) on the assumption that the stock split was conducted at the beginning of FY2013.

Research and development (R&D) expenses

(Millions of yen)

	First nine months of FY2013	**First nine months of FY2014**	Change
R&D expenses	138,554	**148,000**	+9,446

Impact of exchange rate on financial results

The exchange rates for the yen in the first nine months of FY2014 are shown in the table below. The resulting impacts were a ¥36.4 billion increase in sales and a ¥14.8 billion increase in core operating profit.

Average rate	First nine months of FY2013	**First nine months of FY2014**	Change
¥/US$	¥99	**¥107**	¥7 (Weakening of yen)
¥/€	¥132	**¥140**	¥8 (Weakening of yen)

Change from beginning to end of period	As of December 31, 2013	**As of December 31, 2014**
¥/US$	¥11 (Weakening of yen)	**¥18 (Weakening of yen)**
¥/€	¥24 (Weakening of yen)	**¥5 (Weakening of yen)**

Sales

Consolidated sales in the first nine months of FY2014 increased by 9.7% compared to those in the corresponding period of the previous fiscal year ("year-on-year") to ¥952.8 billion.

- In addition to a new product, XTANDI for the treatment of prostate cancer, sales of overactive bladder (OAB) treatments Vesicare and Betanis / Myrbetriq / BETMIGA grew. Additionally, sales of products including Prograf, an immunosuppressant, increased.

Sales by region

*Sales by region calculated according to locations of sellers.

<Japan>

Sales in Japan decreased by 5.3% year-on-year to ¥388.6 billion. Sales in the Japanese market decreased by 6.0% year-on-year to ¥375.3 billion. The impacts of NHI drug price revision enforced in April 2014, generics and other factors caused overall sales to decline year-on-year.

- In addition to Betanis, new products such as Cimzia for the treatment of adult patients with rheumatoid arthritis and Gonax for the treatment of prostate cancer saw growth in sales. Additionally, there were contributions from sales of the selective SGLT2 inhibitor Suglat and XTANDI, which were launched in April and May 2014, respectively.
- On the other hand, sales of products declined, including Lipitor for the treatment of hypercholesterolemia, Seroquel for the treatment of schizophrenia, Myslee for the treatment of insomnia, Gaster for the treatment of peptic ulcer and gastritis, and Harnal for the treatment of functional symptoms of benign prostatic hyperplasia, mainly due to the impacts of NHI drug price revision and generics.
- Furthermore, there were decreases in sales of products including the anti-inflammatory and anti-pain drug Celecox, Symbicort for the treatment of bronchial asthma and Bonoteo for the treatment of osteoporosis, partly reflecting temporary fluctuations in supply and

demand conditions before and after the consumption tax hike implemented in April 2014.

<The Americas>

Sales in the Americas increased by 23.5% year-on-year to ¥268.3 billion. The sales on a U.S. dollar basis increased by 14.9% year-on-year to US$2,511 million.

- In addition to the sales of XTANDI, overall sales of OAB treatments VESIcare and Myrbetriq grew.
- Additionally, there were increases in sales of Prograf and income from anticancer drug Tarceva and others.

<Europe*>

Sales in Europe increased by 23.1% year-on-year to ¥243.3 billion. The sales on a euro basis increased by 16.1% year-on-year to €1,734 million.

- In addition to XTANDI and overall OAB treatments Vesicare and BETMIGA, sales of Prograf, the Candin-type antifungal agent MYCAMINE and others grew.

* This category includes sales from the Middle East, and Africa in addition to Europe.

<Asia and Oceania>

Sales in Asia and Oceania increased by 21.6% year-on-year to ¥52.5 billion.

- Products such as Prograf, Harnal and Vesicare showed growth in sales, resulting in an increase in revenue.

Core operating profit / Core profit for the period

- The increase in sales and a fall in the cost-to-sales ratio resulted in a gross profit of ¥693.3 billion, up 14.1% year-on-year. The cost-to-sales ratio fell 2.8 percentage points year-on-year to 27.2%, owing to changes in product mix and other factors.
- Selling, general and administrative expenses increased by 12.1% year-on-year to ¥317.2 billion, which in addition to the foreign exchange rate impact, was partly due to increased expenditures for co-promotion of XTANDI in the US.
- Research and development (R&D) expenses were ¥148.0 billion, up 6.8% year-on-year, which in addition to the foreign exchange rate impact, was partly due to increased expenses related to progress of development projects. The R&D cost-to-sales ratio was down 0.4 percentage points year-on-year to 15.5%.
- Amortisation of intangible assets was ¥28.0 billion, up 4.3% year-on-year.

As a result of the above, core operating profit increased by 24.7% year-on-year to ¥200.2 billion. Core profit for the period increased by 24.6% to ¥140.3 billion. Core earnings per share increased by 26.8% to ¥63.42.

<Consolidated financial results (full basis)>

Consolidated financial results on a full basis in the first nine months of FY2014 are shown in the table below. Sales, operating profit, profit before tax and profit for the period increased.

Items excluded from results on a core basis including impairment losses for other intangible assets, net foreign exchange losses, restructuring costs and litigation costs at a total of ¥42.6 billion (compared to ¥48.5 billion in the same period of the previous fiscal year) were recorded in "other expense."

Consolidated financial results (full basis)

(Millions of yen)

	First nine months of FY2013	**First nine months of FY2014**	Change (%)
Sales	868,263	**952,772**	+84,509 (+9.7%)
Operating profit	112,875	**161,680**	+48,805 (+43.2%)
Profit before tax	115,437	**161,617**	+46,181 (+40.0%)
Profit for the period	83,456	**114,744**	+31,288 (+37.5%)
Earnings per share (yen)	37.06	**51.87**	+14.81 (+39.9%)
Comprehensive income	191,747	**197,624**	+5,877 (+3.1%)

(Note) The Company conducted a stock split of common stock at a ratio of 5 for 1 with an effective date of April 1, 2014. Earnings per share is calculated based on the number of issued shares after the stock split (excluding treasury shares) on the assumption that the stock split was conducted at the beginning of FY2013.

(2) Information on financial position

1) Assets, equity and liabilities

An overview of the consolidated statement of financial position as of December 31, 2014 and the main changes from the end of the previous fiscal year are shown below.

Assets

Total assets as of December 31, 2014 saw an increase of ¥198.7 billion compared to the end of the previous fiscal year to ¥1,851.8 billion.

<Non-current assets> ¥810.0 billion (an increase of ¥70.1 billion)

- Other intangible assets increased by ¥21.0 billion compared to the end of the previous fiscal year to ¥301.2 billion.

<Current assets> ¥1,041.9 billion (an increase of ¥128.6 billion)

- Cash and cash equivalents increased by ¥46.6 billion compared to the end of the previous fiscal year to ¥438.0 billion.

Equity

Total equity as of December 31, 2014 saw an increase of ¥105.7 billion compared to the end of the previous fiscal year to ¥1,374.2 billion, making the ratio of owners' equity to gross assets 74.2%.

- While profit for the period stood at ¥114.7 billion, the Company paid ¥62.1 billion of dividends of surplus and acquired ¥30.0 billion of own shares.
- Cancellation of treasury shares totaling ¥25.4 billion (25 million shares) was carried out on May 30, 2014.
- In addition, the effect of foreign currency translation adjustments increased equity by ¥77.9 billion.

Liabilities

Total liabilities increased by ¥93.0 billion compared to the end of the previous fiscal year to ¥477.7 billion.

<Non-current liabilities> ¥53.2 billion (an increase of ¥9.3 billion)

<Current liabilities> ¥424.4 billion (an increase of ¥83.7 billion)

2) Cash flow

Cash flows from operating activities

Net cash flows from operating activities decreased year-on-year by ¥9.2 billion to ¥154.6 billion.

- Income tax paid was ¥49.5 billion, an increase in outflow of ¥23.1 billion year-on-year.

Cash flows from investing activities

Net cash flows used in investing activities was ¥48.3 billion, an increase in outflow of ¥12.4 billion year-on-year.

- Purchases of property, plant and equipment used cash of ¥12.4 billion and purchase of intangible assets used cash of ¥41.1 billion, while proceeds from sales of property, plant and equipment provided cash of ¥5.3 billion.

Cash flows from financing activities

Net cash flows used in financing activities was ¥92.7 billion, an increase in outflow of ¥3.6 billion year-on-year.

- Dividends paid totaled ¥62.1 billion, an increase in outflow of ¥3.5 billion year-on-year. Other outflow included cash of ¥30.0 billion used for the acquisition of own shares.

As a result of the above, cash and cash equivalents totaled ¥438.0 billion as of December 31, 2014, an increase of ¥46.6 billion compared to the end of the previous fiscal year.

(3) Information on consolidated business forecasts for FY2014 and other forward-looking statements

The Company's business forecasts for FY2014 are presented on a core basis.
The consolidated full-year business forecasts (core basis) for the fiscal year ending March 31, 2015 (FY2014) are shown below. The Company has left its business forecasts unchanged from the consolidated full-year business forecasts announced in October 2014.

Consolidated full-year business forecasts (core basis)

(Millions of yen)

	FY2013 Full-year results	**FY2014** **Full-year forecasts**	Change (%)
Sales	1,139,909	**1,210,000**	+70,091 (+6.1%)
Core operating profit	186,253	**210,000**	+23,747 (+12.7%)
Core profit for the year	132,796	**154,000**	+21,204 (+16.0%)
Core earnings per share (yen)	59.11	**69.65**	+10.54 (+17.8%)

(Note1) Expected exchange rates for consolidated full-year forecasts announced in October 2014 are ¥104/US$ and ¥137/€.
Exchange rates for FY2013 were ¥100/US$ and ¥134/€.

(Note2) The Company conducted a stock split of common stock at a ratio of 5 for 1 with an effective date of April 1, 2014. Core earnings per share is calculated based on the number of issued shares after the stock split (excluding treasury shares) on the assumption that the stock split was conducted at the beginning of FY2013. In addition, acquisitions of own shares carried out from May 13 to June 23, 2014 are reflected in the figures.

2. Matters Related to Summary Information (Notes)

(1) Changes in Accounting Policies and Accounting Estimates

The significant accounting policies adopted for the Group's condensed interim consolidated financial statements for the nine months ended 31 December 2014 are the same as those applied for its consolidated financial statements for the fiscal year ended 31 March 2014, except for the new standards listed below.

The Group calculated income tax expense for the nine months ended 31 December 2014 based on the estimated average annual effective tax rate.

The following accounting standards and interpretations are newly applied by the Group from the three months ended 30 June 2014 in compliance with each transitional provision. These standards and interpretations do not have a material impact on the Group's condensed interim consolidated financial statements.

IFRS		Summary of new standards and amendments
IAS 32	Financial Instruments: Presentation	Offsetting financial assets and financial liabilities
IAS 36	Impairment of Assets	Disclosures related to recoverable amount of non-financial assets
IFRS 10	Consolidated Financial Statements	Establishment of accounting treatment for entities meeting new definition of investment entity
IFRS 12	Disclosure of Interests in Other Entities	Additional disclosure requirements for newly defined investment entities
IFRIC 21	Levies	Clarification of recognition of liabilities for levies

3. Condensed Interim Consolidated Financial Statements

(1) Condensed Interim Consolidated Statements of Income

（Millions of Yen）

	Nine months ended 31 December 2013	Nine months ended 31 December 2014
Sales	868,263	952,772
Cost of sales	(260,677)	(259,478)
Gross profit	607,586	693,294
Selling, general and administrative expenses	(283,004)	(317,228)
Research and development expenses	(138,554)	(148,000)
Amortisation of intangible assets	(26,854)	(28,015)
Share of profits of associates and joint ventures	1,407	142
Other income	790	4,127
Other expense	(48,496)	(42,640)
Operating profit	112,875	161,680
Finance income	3,559	2,870
Finance expense	(998)	(2,933)
Profit before tax	115,437	161,617
Income tax expense	(31,981)	(46,873)
Profit for the period	83,456	114,744
Profit attributable to:		
Owners of the parent	83,456	114,744
Earnings per share		
Basic（Yen）	37.06	51.87
Diluted（Yen）	37.01	51.79

(2) Condensed Interim Consolidated Statements of Comprehensive Income

(Millions of Yen)

	Nine months ended 31 December 2013	Nine months ended 31 December 2014
Profit for the period	83,456	114,744
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Remeasurements of defined benefit plans	3,925	(1,079)
Total items that will not be reclassified subsequently to profit or loss	3,925	(1,079)
Items that may be reclassified subsequently to profit or loss		
Foreign currency translation adjustments	98,372	77,945
Fair value movements on available-for-sale financial assets	5,995	6,015
Total items that may be reclassified subsequently to profit or loss	104,366	83,959
Other comprehensive income, net of tax	108,291	82,880
Total comprehensive income	191,747	197,624
Total comprehensive income attributable to:		
Owners of the parent	191,747	197,624

(3) Condensed Interim Consolidated Statements of Financial Position

(Millions of Yen)

	As of 31 March 2014	As of 31 December 2014
Assets		
Non-current assets		
Property, plant and equipment	191,451	205,932
Goodwill	116,766	136,768
Other intangible assets	280,120	301,156
Investments in associates and joint ventures	1,808	1,945
Deferred tax assets	45,530	44,698
Other financial assets	94,961	105,263
Other non-current assets	9,179	14,203
Total non-current assets	739,816	809,964
Current assets		
Inventories	135,228	153,318
Trade and other receivables	332,639	394,962
Income tax receivable	2,710	4,060
Other financial assets	35,406	37,651
Other current assets	12,068	13,887
Cash and cash equivalents	391,374	438,008
Sub total	909,424	1,041,886
Assets held for sale	3,868	—
Total current assets	913,292	1,041,886
Total assets	1,653,108	1,851,850

(Millions of Yen)

	As of 31 March 2014	As of 31 December 2014
Equity and liabilities		
Equity		
Share capital	103,001	103,001
Capital surplus	176,822	176,822
Treasury shares	(54,535)	(58,879)
Retained earnings	864,830	890,813
Other components of equity	178,359	262,429
Total equity attributable to owners of the parent	1,268,476	1,374,186
Total equity	1,268,476	1,374,186
Liabilities		
Non-current liabilities		
Trade and other payables	64	90
Deferred tax liabilities	2	74
Retirement benefit liabilities	27,184	31,031
Provisions	4,264	2,904
Other financial liabilities	749	653
Other non-current liabilities	11,681	18,483
Total non-current liabilities	43,944	53,235
Current liabilities		
Trade and other payables	187,032	220,063
Income tax payable	13,237	16,663
Provisions	66,407	96,425
Other financial liabilities	1,062	14,363
Other current liabilities	72,950	76,916
Total current liabilities	340,688	424,429
Total liabilities	384,632	477,664
Total equity and liabilities	1,653,108	1,851,850

(4) Condensed Interim Consolidated Statements of Changes in Equity

(Millions of Yen)

	Equity attributable to owners of the parent					
					Other components of equity	
	Share capital	Capital surplus	Treasury shares	Retained earnings	Subscription rights to shares	Foreign currency translation adjustments
As of 1 April 2013	103,001	176,822	(72,285)	875,473	1,937	67,659
Comprehensive income						
Profit for the period	—	—	—	83,456	—	—
Other comprehensive income	—	—	—	—	—	98,372
Total comprehensive income	—	—	—	83,456	—	98,372
Transactions with owners of the parent						
Acquisition of treasury shares	—	—	(30,056)	—	—	—
Disposals of treasury shares	—	—	337	(106)	(148)	—
Cancellation of treasury shares	—	—	47,362	(47,362)	—	—
Dividends	—	—	—	(58,656)	—	—
Share-based payments	—	—	—	—	275	—
Transfers	—	—	—	3,925	—	—
Total transactions with owners of the parent	—	—	17,643	(102,199)	128	—
As of 31 December 2013	103,001	176,822	(54,642)	856,729	2,064	166,031

As of 1 April 2014	103,001	176,822	(54,535)	864,830	2,110	147,660
Comprehensive income						
Profit for the period	—	—	—	114,744	—	—
Other comprehensive income	—	—	—	—	—	77,945
Total comprehensive income	—	—	—	114,744	—	77,945
Transactions with owners of the parent						
Acquisition of treasury shares	—	—	(30,012)	—	—	—
Disposals of treasury shares	—	—	270	(138)	(123)	—
Cancellation of treasury shares	—	—	25,398	(25,398)	—	—
Dividends	—	—	—	(62,146)	—	—
Share-based payments	—	—	—	—	234	—
Transfers	—	—	—	(1,079)	—	—
Total transactions with owners of the parent	—	—	(4,344)	(88,761)	111	—
As of 31 December 2014	103,001	176,822	(58,879)	890,813	2,221	225,605

(Millions of Yen)

	Equity attributable to owners of the parent				Total equity
	Other components of equity			Total	
	Fair value movements on available-for-sale financial assets	Remeasurements of defined benefit plans	Total		
As of 1 April 2013	22,000	—	91,596	1,174,606	1,174,606
Comprehensive income					
Profit for the period	—	—	—	83,456	83,456
Other comprehensive income	5,995	3,925	108,291	108,291	108,291
Total comprehensive income	5,995	3,925	108,291	191,747	191,747
Transactions with owners of the parent					
Acquisition of treasury shares	—	—	—	(30,056)	(30,056)
Disposals of treasury shares	—	—	(148)	83	83
Cancellation of treasury shares	—	—	—	—	—
Dividends	—	—	—	(58,656)	(58,656)
Share-based payments	—	—	275	275	275
Transfers	—	(3,925)	(3,925)	—	—
Total transactions with owners of the parent	—	(3,925)	(3,798)	(88,354)	(88,354)
As of 31 December 2013	27,995	—	196,090	1,278,000	1,278,000
As of 1 April 2014	28,588	—	178,359	1,268,476	1,268,476
Comprehensive income					
Profit for the period	—	—	—	114,744	114,744
Other comprehensive income	6,015	(1,079)	82,880	82,880	82,880
Total comprehensive income	6,015	(1,079)	82,880	197,624	197,624
Transactions with owners of the parent					
Acquisition of treasury shares	—	—	—	(30,012)	(30,012)
Disposals of treasury shares	—	—	(123)	8	8
Cancellation of treasury shares	—	—	—	—	—
Dividends	—	—	—	(62,146)	(62,146)
Share-based payments	—	—	234	234	234
Transfers	—	1,079	1,079	—	—
Total transactions with owners of the parent	—	1,079	1,190	(91,915)	(91,915)
As of 31 December 2014	34,603	—	262,429	1,374,186	1,374,186

(5) Condensed Interim Consolidated Statements of Cash Flows

(Millions of Yen)

	Nine months ended 31 December 2013	Nine months ended 31 December 2014
Cash flows from operating activities		
Profit before tax	115,437	161,617
Depreciation and amortisation	47,937	48,072
Impairment losses and reversal of impairment losses	32,969	9,145
Finance income and expense	(2,561)	63
(Increase) decrease in inventories	(929)	(6,043)
(Increase) decrease in trade and other receivables	(21,883)	(43,715)
Increase (decrease) in trade and other payables	(16,916)	6,310
Other	36,050	28,597
Cash generated from operations	190,103	204,047
Income tax paid	(26,371)	(49,485)
Net cash flows from operating activities	163,732	154,561
Cash flows from investing activities		
Purchases of property, plant and equipment	(19,250)	(12,420)
Proceeds from sales of property, plant and equipment	1,041	5,341
Purchase of intangible assets	(19,775)	(41,062)
Purchase of available-for-sale financial assets	(1,452)	(3,226)
Proceeds from sales of available-for-sale financial assets	3,603	4,084
Interest and dividends received	2,916	2,071
Other	(2,917)	(3,044)
Net cash flows used in investing activities	(35,834)	(48,257)
Cash flows from financing activities		
Acquisition of treasury shares	(30,056)	(30,012)
Dividends paid to owners of the parent	(58,656)	(62,146)
Other	(460)	(567)
Net cash flows used in financing activities	(89,172)	(92,724)
Effect of exchange rate changes on cash and cash equivalents	35,702	33,054
Net increase (decrease) in cash and cash equivalents	74,428	46,634
Cash and cash equivalents at the beginning of the year	264,912	391,374
Cash and cash equivalents at the end of the period	339,340	438,008

(6) Notes on going concern assumption

Not applicable.

Supplement Documents [IFRS]

Financial results for the first nine months of the fiscal year 2014 (FY2014)

ending March 31, 2015.

Astellas Pharma Inc.

- Financial Results of 3Q/FY2014
  - Nine months ended December 31, 2014
  - Three months ended December 31, 2014
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

[Nine months ended December 31, 2014]

1. Consolidated Results (Full Basis)

billion yen

	FY13 APR. - DEC.	FY14 APR. - DEC.	Change	Change (%)	FY13 Full Year
Sales	868.3	952.8	84.5	9.7%	1,139.9
Cost of sales	260.7	259.5	-1.2	-0.5%	330.6
Ratio to Sales	30.0%	27.2%			29.0%
Gross profit	607.6	693.3	85.7	14.1%	809.3
SG&A expenses	283.0	317.2	34.2	12.1%	397.0
Ratio to Sales	32.6%	33.3%			34.8%
Advertising and Sales Promotion	79.9	93.2	13.2	16.5%	112.1
Personnel expenses	122.8	129.8	6.9	5.7%	167.8
Other	80.2	94.3	14.1	17.5%	117.0
R&D expenses	138.6	148.0	9.4	6.8%	191.5
Ratio to Sales	16.0%	15.5%			16.8%
Amortisation of intangible assets	26.9	28.0	1.2	4.3%	36.0
Share of profits of associates and joint ventures	1.4	0.1	-1.3	-89.9%	1.5
Other income	0.8	4.1	3.3	422.2%	11.6
Gain on sales of property, plant and equipment	0.1	1.4	1.3	-	5.5
Other expense	48.5	42.6	-5.9	-12.1%	81.0
Loss on sales and disposal of property, plant and equipment	0.5	0.7	0.3	56.8%	4.1
Impairment losses	33.2	9.1	-24.0	-72.4%	55.8
Restructuring costs	9.2	11.5	2.3	24.7%	10.1
Net foreign exchange losses	4.7	10.0	5.3	111.4%	8.0
Litigation costs	0.2	11.0	10.8	-	0.2
Operating profit	112.9	161.7	48.8	43.2%	116.8
Ratio to Sales	13.0%	17.0%			10.2%
Finance income	3.6	2.9	-0.7	-19.4%	6.8
Gain on sales of available-for-sale financial assets	2.2	1.1	-1.1	-49.5%	5.0
Finance expense	1.0	2.9	1.9	193.8%	1.7
Impairment losses for available-for-sale financial assets	0.7	2.6	1.9	261.2%	1.2
Profit before tax	115.4	161.6	46.2	40.0%	122.0
Ratio to Sales	13.3%	17.0%			10.7%
Income tax expense	32.0	46.9	14.9	46.6%	31.1
Profit for the period	83.5	114.7	31.3	37.5%	90.9
Ratio to Sales	9.6%	12.0%			8.0%
Comprehensive income	191.7	197.6	5.9	3.1%	182.1

2. Consolidated Results (Core Basis)

billion yen

	FY13 APR. - DEC.	FY14 APR. - DEC.	Change	Change (%)	FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Sales	868.3	952.8	84.5	9.7%	1,139.9	1,210.0	6.1%
Cost of sales	260.7	259.5	-1.2	-0.5%	330.6		
Ratio to Sales	30.0%	27.2%			29.0%		
Gross profit	607.6	693.3	85.7	14.1%	809.3		
SG&A expenses	283.0	317.2	34.2	12.1%	397.0		
Ratio to Sales	32.6%	33.3%			34.8%		
Advertising and Sales Promotion	79.9	93.2	13.2	16.5%	112.1		
Personnel expenses	122.8	129.8	6.9	5.7%	167.8		
Other	80.2	94.3	14.1	17.5%	117.0		
R&D expenses	138.6	148.0	9.4	6.8%	191.5	200.0	4.5%
Ratio to Sales	16.0%	15.5%			16.8%	16.5%	
Amortisation of intangible assets	26.9	28.0	1.2	4.3%	36.0		
Share of profits of associates and joint ventures	1.4	0.1	-1.3	-89.9%	1.5		
Operating profit	160.6	200.2	39.6	24.7%	186.3	210.0	12.7%
Ratio to Sales	18.5%	21.0%			16.3%	17.4%	
Finance income	1.4	1.8	0.4	27.5%	1.6		
Finance expense	0.3	0.3	0.0	4.3%	0.4		
Profit before Tax	161.7	201.7	40.0	24.7%	187.5		
Ratio to Sales	18.6%	21.2%			16.4%		
Income tax expense	49.1	61.4	12.3	25.0%	54.7		
Profit for the period	112.6	140.3	27.7	24.6%	132.8	154.0	16.0%
Ratio to Sales	13.0%	14.7%			11.6%	12.7%	

3. Exchange Rate

yen

	FY13 APR. - DEC.Ave.	FY14 APR. - DEC.Ave.	FY13 End	FY14 3Q End	FY13 Full Year	Forecasts FY14 Full Year
Yen/USD	99	107	103	121	100	104
Yen/EUR	132	140	142	147	134	137

∗ Exchange rate fluctuations had positive impact by 36.4 billion yen on sales and positive impact by 14.8 billion yen on Core operating profit in Q3/FY2014

4. Reconciliation of Full Basis to Core Basis

Billion yen

	FY13 APR. - DEC.			FY14 APR. - DEC.		
Account item	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**868.3**	**-**	**868.3**	**952.8**	**-**	**952.8**
Cost of sales	260.7	-	260.7	259.5	-	259.5
Gross profit	**607.6**	**-**	**607.6**	**693.3**	**-**	**693.3**
SG&A expenses	283.0	-	283.0	317.2	-	317.2
R&D expenses	138.6	-	138.6	148.0	-	148.0
Amortisation of intangible assets	26.9	-	26.9	28.0	-	28.0
Share of profits of associates and joint ventures	1.4	-	1.4	0.1	-	0.1
Other income *1	0.8	-0.8	-	4.1	-4.1	-
Other expense *1	48.5	-48.5	-	42.6	-42.6	-
Operating profit	**112.9**	**47.7**	**160.6**	**161.7**	**38.5**	**200.2**
Finance income *2	3.6	-2.2	1.4	2.9	-1.1	1.8
Finance expense *2	1.0	-0.7	0.3	2.9	-2.6	0.3
Profit before tax	**115.4**	**46.3**	**161.7**	**161.6**	**40.1**	**201.7**
Income tax expense	32.0	17.1	49.1	46.9	14.5	61.4
Profit for the period	**83.5**	**29.1**	**112.6**	**114.7**	**25.5**	**140.3**

*1. “Other income” and “Other expense” are excluded from Core results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses for other intangible assets, restructuring costs, litigation costs and net foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results.

5. Segment Information by Region

billion yen

		FY13 APR. - DEC.	FY14 APR. - DEC.	Change	Change (%)	FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 (%)
Sales		868.3	952.8	84.5	9.7%	1,139.9	1,210.0	6.1%
	Japan	410.2	388.6	-21.6	-5.3%	530.6	503.0	-5.2%
	Ratio to Sales	47.2%	40.8%			46.5%	41.6%	
	Americas	217.3	268.3	51.0	23.5%	287.0	328.9	14.6%
	Ratio to Sales	25.0%	28.2%			25.2%	27.2%	
	Europe	197.6	243.3	45.7	23.1%	264.3	307.6	16.4%
	Ratio to Sales	22.8%	25.5%			23.2%	25.4%	
	Asia and Oceania	43.2	52.5	9.3	21.6%	58.0	70.4	21.5%
	Ratio to Sales	5.0%	5.5%			5.1%	5.8%	

- Calculated according to locations of sellers.
- Europe: Including Middle and East and Africa

6. Depreciation/Amortisation

billion yen

		FY13 APR. - DEC.	FY14 APR. - DEC.	Change	Change (%)	billion yen FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 (%)
Depreciation(Tangible)								
	Consolidated	17.3	16.0	-1.3	-7.7%	23.2	23.0	-0.8%
Amortisation(Intangible) *								
	Consolidated	30.6	32.1	1.5	4.8%	41.1	43.0	4.6%

* Amortisation(Intangible): Including amortisation of software, etc.

7. Sales of major products

1)Sales of global products

billion yen

	FY13 APR. - DEC.	FY14 APR. - DEC.	Change	Change (%)	billion yen FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Prograf	137.3	147.8	10.5	7.6%	181.1	187.5	3.6%
Sales by Astellas	133.7	145.3	11.6	8.7%	175.9	184.0	4.6%
Japan (Including Graceptor)	39.1	37.3	-1.9	-4.7%	50.4	48.6	-3.6%
Americas	23.3	25.6	2.4	10.2%	29.6	32.5	9.6%
Europe	53.0	59.4	6.4	12.1%	70.8	73.2	3.3%
Advagraf	17.7	21.7	4.0	22.7%	24.0		
Asia and Oceania	18.3	23.0	4.6	25.3%	25.0	29.8	19.2%
Exports to third parties	3.6	2.5	-1.1	-29.7%	5.2	3.5	-31.7%
Harnal	46.4	42.9	-3.4	-7.4%	59.5	56.4	-5.2%
Sales by Astellas	42.8	40.2	-2.6	-6.2%	55.2	52.1	-5.5%
Japan	16.0	11.8	-4.2	-26.3%	20.2	14.9	-26.6%
Europe	15.1	14.8	-0.3	-2.0%	19.4	18.6	-3.8%
Asia and Oceania	11.2	13.2	1.9	17.2%	14.9	18.1	21.4%
Bulk and Royalties	3.5	2.7	-0.8	-22.5%	4.3	4.3	-1.6%
Vesicare	100.4	104.2	3.8	3.8%	133.8	129.9	-3.0%
Japan	22.2	19.3	-2.9	-13.1%	30.7	26.9	-12.5%
Americas	44.3	47.8	3.5	7.9%	58.1	55.7	-4.1%
Europe	30.6	32.9	2.2	7.3%	40.8	41.7	2.2%
Asia and Oceania	3.0	3.8	0.8	27.1%	3.8	5.1	32.9%
Betanis/Myrbetriq/Betmiga	19.1	37.8	18.7	98.0%	28.2	52.4	85.7%
Japan	8.0	10.5	2.5	31.1%	11.6	14.7	26.8%
Americas	9.9	19.9	10.0	101.5%	14.5	26.9	85.5%
Europe	1.2	7.2	6.1	522.9%	2.1	10.3	400.1%
Funguard/Mycamine	27.7	29.8	2.2	7.8%	36.1	38.1	5.5%
Japan	9.8	9.3	-0.4	-4.4%	12.3	11.9	-3.3%
Americas	9.1	9.2	0.1	1.3%	11.7	11.3	-3.9%
Europe	6.5	8.2	1.7	26.7%	8.6	10.7	24.2%
Asia and Oceania	2.4	3.1	0.7	31.6%	3.4	4.1	22.7%
Protopic	18.8	18.0	-0.8	-4.5%	25.0	19.7	-21.1%
Americas	9.3	9.7	0.4	4.2%	11.7	9.0	-22.5%
Europe	4.9	5.7	0.9	18.0%	7.1	7.5	6.8%
Asia and Oceania	1.9	2.5	0.6	31.7%	2.6	3.1	21.5%
XTANDI	36.8	94.9	58.1	158.1%	54.6		
US	31.5	59.4	27.8	88.4%	44.3	71.8	62.2%
ex-US	5.3	35.6	30.3	574.8%	10.3		
Japan	-	10.2	10.2	-	-		
Americas (ex-US)	0.5	1.9	1.4	273.5%	0.8		
Europe	4.8	23.1	18.4	386.8%	9.5	31.5	233.2%
Asia and Oceania	0.0	0.3	0.3	-	0.0		
Eligard	13.6	14.6	1.0	7.3%	18.3		
Europe	13.6	14.6	1.0	7.2%	18.3	19.6	7.1%
Asia and Oceania	0.0	0.0	0.0	307.7%	0.0		

- Sales of products in Japan are shown in a gross sales basis.
- Europe: Including Middle and East and Africa

2)Sales of products in Japan

billion yen

<Global products>	FY13 APR. - DEC.	FY14 APR. - DEC.	Change	Change (%)	FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Prograf （Including Graceptor）	39.1	37.3	-1.9	-4.7%	50.4	48.6	-3.6%
Harnal	16.0	11.8	-4.2	-26.3%	20.2	14.9	-26.6%
Vesicare	22.2	19.3	-2.9	-13.1%	30.7	26.9	-12.5%
Betanis	8.0	10.5	2.5	31.1%	11.6	14.7	26.8%
Funguard	9.8	9.3	-0.4	-4.4%	12.3	11.9	-3.3%
XTANDI	-	10.2	10.2	-	-		
<Local products in Japan>							
Lipitor [Family]	49.5	37.0	-12.5	-25.2%	62.4	47.1	-24.5%
Caduet	8.2	7.9	-0.3	-3.4%	10.7		
Micardis [Family]	75.6	75.1	-0.5	-0.7%	97.6	99.3	1.7%
Micombi	9.2	8.4	-0.7	-7.9%	11.8		
Micamlo	16.2	18.4	2.2	13.7%	21.4		
Gaster	20.4	14.2	-6.2	-30.4%	25.7	17.9	-30.5%
Myslee	21.9	15.1	-6.9	-31.3%	28.2	19.7	-30.2%
Seroquel	15.7	10.0	-5.7	-36.2%	19.6	12.6	-35.6%
Vaccines	29.2	33.5	4.3	14.8%	35.0	37.1	6.2%
Cefzon	5.0	4.0	-1.0	-20.0%	6.4	5.3	-16.9%
Celecox	32.3	31.6	-0.7	-2.1%	44.3	42.6	-3.8%
Geninax	9.4	8.1	-1.2	-13.3%	11.7	12.0	1.7%
Bonoteo	10.3	9.8	-0.5	-5.1%	14.1	13.5	-4.4%
Symbicort	25.7	25.0	-0.7	-2.7%	35.6	35.3	-1.0%
Argamate	4.7	4.6	-0.1	-2.1%	6.1	5.9	-3.4%
Kiklin	1.0	1.2	0.1	13.1%	1.4	1.8	21.9%
Gonax	1.8	2.6	0.8	43.2%	2.5	3.9	51.6%
Cimzia	2.2	3.8	1.6	69.4%	3.2	6.0	85.1%
Suglat	-	3.3	3.3	-	-		
Total Rx Sales In Japanese market	399.4	375.3	-24.1	-6.0%	515.6	487.0	-5.5%

- Sales of products in Japan are shown in a gross sales basis.

3)Sales of products in Americas and Europe

billion yen

		FY13 APR. - DEC.	FY14 APR. - DEC.	Change	Change (%)	FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Scan*	(Americas)	48.1	49.3	1.3	2.6%	61.8	61.1	-1.3%
Lexiscan		45.1	49.1	4.0	8.8%	58.6		
AmBisome	(Americas)	6.4	6.6	0.2	2.8%	8.1	8.3	3.0%
Tarceva		33.8	37.0	3.2	9.4%	44.7		
	(US)	21.7	25.3	3.7	16.9%	28.9		
	(ex-US)	12.1	11.6	-0.5	-4.1%	15.9		
Qutenza	(Europe)	1.0	1.4	0.4	34.3%	1.4		
DIFICLIR	(Europe)	0.9	1.5	0.6	62.8%	1.3		

* Adenoscan + Lexiscan

4)Sales in Americas and Europe(Local currency)

Unit:M$

Americas	FY13 APR. - DEC.	FY14 APR. - DEC.	Change	Change (%)	FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Net Sales	2,186	2,511	325	14.9%	2,863	3,162	10.4%
Prograf	234	240	6	2.5%	296	312	5.6%
Scan*	483	461	-22	-4.6%	617	587	-4.9%
Lexiscan	454	459	5	1.2%	585		
AmBisome	64	61	-3	-4.4%	80	80	-0.7%
Protopic	93	90	-3	-3.0%	116	87	-25.3%
VESIcare	445	447	2	0.4%	580	536	-7.6%
Myrbetriq	99	186	87	87.4%	145	259	78.8%
MYCAMINE	91	86	-5	-5.8%	117	109	-7.4%
Tarceva	340	346	6	1.7%	446		
US	218	237	19	8.7%	288		
ex-US	122	109	-13	-10.8%	158		
XTANDI	322	573	251	78.0%	450		
US	317	555	238	75.2%	441	690	56.3%
Americas (ex-US)	5	18	13	247.4%	8		

* Adenoscan + Lexiscan

Unit:M€

Europe	FY13 APR. - DEC.	FY14 APR. - DEC.	Change	Change (%)	FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Net Sales	1,494	1,734	240	16.1%	1,967	2,246	14.2%
Harnal (Omnic)	141	125	-16	-11.3%	176	167	-5.2%
Sales by Astellas	114	106	-9	-7.7%	144	136	-5.6%
Capsule	56	53	-3	-5.2%	69	69	-0.3%
OCAS	58	53	-6	-10.0%	75	68	-10.5%
Bulk and Royalties	27	20	-7	-27.0%	32	31	-3.4%
Prograf	427	442	14	3.3%	565	560	-1.0%
Sales by Astellas	401	423	23	5.7%	527	534	1.3%
Advagraf	134	155	21	15.7%	179		
Exports to third parties	27	18	-9	-32.0%	38	26	-32.5%
Vesicare	232	234	3	1.2%	303	304	0.3%
BETMIGA	9	51	43	487.1%	15	75	390.6%
Protopic	37	41	4	11.2%	52	55	4.8%
MYCAMINE	49	58	10	19.5%	64	78	21.9%
Eligard	103	104	1	1.0%	136	143	5.1%
Qutenza	8	10	2	27.7%	11		
DIFICLIR	7	11	4	54.7%	9		
XTANDI	36	165	129	358.8%	70	230	226.9%

- Europe: Including Middle and East and Africa

8.Consolidated statements of financial position

Billion yen

			31-Mar-14	31-Dec-14	
			Amount	Amount	Change
Assets			**1,653.1**	**1,851.8**	**198.7**
	Non-current assets		**739.8**	**810.0**	**70.1**
		Property, plant and equipment	191.5	205.9	14.5
		Goodwill	116.8	136.8	20.0
		Other intangible assets	280.1	301.2	21.0
		Investments in associates and joint ventures	1.8	1.9	0.1
		Deferred tax assets	45.5	44.7	-0.8
		Other financial assets	95.0	105.3	10.3
		Other non-current assets	9.2	14.2	5.0
	Current assets		**913.3**	**1,041.9**	**128.6**
		Inventories	135.2	153.3	18.1
		Trade and other receivables	332.6	395.0	62.3
		Income tax receivable	2.7	4.1	1.4
		Other financial assets	35.4	37.7	2.2
		Other current assets	12.1	13.9	1.8
		Cash and cash equivalents	391.4	438.0	46.6
		Assets held for sale	3.9	-	-3.9

Billion yen

	31-Mar-14	31-Dec-14	
	Amount	Amount	Change
Equity and Liabilities	**1,653.1**	**1,851.8**	**198.7**
Equity	**1,268.5**	**1,374.2**	**105.7**
Equity attributable to owners of the parent	**1,268.5**	**1,374.2**	**105.7**
Share capital	103.0	103.0	-
Capital surplus	176.8	176.8	-
Treasury shares	-54.5	-58.9	-4.3
Retained earnings	864.8	890.8	26.0
Other components of equity	178.4	262.4	84.1
Liabilities	**384.6**	**477.7**	**93.0**
Non-current liabilities	**43.9**	**53.2**	**9.3**
Trade and other payables	0.1	0.1	0.0
Deferred tax liabilities	0.0	0.1	0.1
Retirement benefit liabilities	27.2	31.0	3.8
Provisions	4.3	2.9	-1.4
Other financial liabilities	0.7	0.7	-0.1
Other non-current liabilities	11.7	18.5	6.8
Current liabilities	**340.7**	**424.4**	**83.7**
Trade and other payables	187.0	220.1	33.0
Income tax payable	13.2	16.7	3.4
Provisions	66.4	96.4	30.0
Other financial liabilities	1.1	14.4	13.3
Other current liabilities	73.0	76.9	4.0

[Three months ended December 31, 2014]

1. Consolidated Results (Full Basis)

bilion yen

	FY14					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Sales	295.2	9.5%	299.3	9.0%	358.3	10.5%
Cost of sales	76.0	-6.4%	83.1	4.5%	100.4	0.4%
Ratio to Sales	25.7%		27.8%		28.0%	
Gross profit	219.2	16.4%	216.2	10.8%	257.9	15.0%
SG&A expenses	96.9	6.3%	104.9	12.3%	115.5	17.2%
Ratio to Sales	32.8%		35.0%		32.2%	
Advertising and Sales Promotion	28.2	15.1%	26.8	0.6%	38.1	32.4%
Personnel expenses	42.4	3.0%	42.9	9.2%	44.5	5.0%
Other	26.3	3.2%	35.1	28.1%	32.9	20.3%
R&D expenses	47.6	8.0%	49.4	6.6%	51.0	5.9%
Ratio to Sales	16.1%		16.5%		14.2%	
Amortisation of intangible assets	8.9	0.8%	9.1	0.9%	10.1	11.1%
Share of profits of associates and joint ventures	0.2	-1.6%	0.3	-65.6%	-0.4	-263.7%
Other income	2.7	-	2.9	470.8%	1.0	518.2%
Gain on sales of property, plant and equipment	0.0	27.9%	1.4	-	0.0	-64.8%
Net foreign exchange gains	2.5	-	-	-	-	-
Other expense	18.1	-0.6%	3.5	-66.8%	23.5	18.8%
Loss on sales and disposal of property, plant and equipment	0.2	20.2%	0.4	406.3%	0.2	-26.6%
Impairment losses	8.1	-30.3%	0.3	-95.8%	0.8	-94.8%
Restructuring costs	9.3	99.5%	2.0	-28.8%	0.2	-89.1%
Net foreign exchange losses	-	-	0.7	-19.2%	11.7	464.9%
Litigation costs	0.5	-	0.0	-90.9%	10.5	-
Operating profit	50.6	91.5%	52.6	40.9%	58.5	19.1%
Ratio to Sales	17.1%		17.6%		16.3%	
Finance income	1.8	183.5%	0.4	-70.7%	0.6	-57.0%
Gain on sales of available-for-sale financial assets	0.9	-	0.2	-85.1%	0.1	-94.3%
Finance expense	2.1	213.3%	0.7	898.8%	0.1	-42.8%
Impairment losses for available-for-sale financial assets	2.0	220.1%	0.6	-	-	-
Profit before tax	50.3	90.6%	52.4	35.0%	58.9	17.3%
Ratio to Sales	17.0%		17.5%		16.5%	
Income tax expense	14.4	120.0%	18.3	39.8%	14.2	14.8%
Profit for the period	35.9	80.9%	34.1	32.6%	44.8	18.1%
Ratio to Sales	12.1%		11.4%		12.5%	
Comprehensive income	22.5	-59.8%	65.3	112.8%	109.8	4.6%

2. Consolidated Results (Core Basis)

bilion yen

	FY14					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Sales	295.2	9.5%	299.3	9.0%	358.3	10.5%
Cost of sales	76.0	-6.4%	83.1	4.5%	100.4	0.4%
Ratio to Sales	25.7%		27.8%		28.0%	
Gross profit	219.2	16.4%	216.2	10.8%	257.9	15.0%
SG&A expenses	96.9	6.3%	104.9	12.3%	115.5	17.2%
Ratio to Sales	32.8%		35.0%		32.2%	
Advertising and Sales Promotion	28.2	15.1%	26.8	0.6%	38.1	32.4%
Personnel expenses	42.4	3.0%	42.9	9.2%	44.5	5.0%
Other	26.3	3.2%	35.1	28.1%	32.9	20.3%
R&D expenses	47.6	8.0%	49.4	6.6%	51.0	5.9%
Ratio to Sales	16.1%		16.5%		14.2%	
Amortisation of intangible assets	8.9	0.8%	9.1	0.9%	10.1	11.1%
Share of profits of associates and joint ventures	0.2	-1.6%	0.3	-65.6%	-0.4	-263.7%
Operating profit	66.0	48.2%	53.2	12.4%	81.0	17.8%
Ratio to Sales	22.4%		17.8%		22.6%	
Finance income	1.0	55.6%	0.3	-1.2%	0.5	7.9%
Finance expense	0.1	112.4%	0.1	-8.3%	0.1	-24.0%
Profit before Tax	66.8	48.3%	53.4	12.4%	81.4	17.8%
Ratio to Sales	22.6%		17.8%		22.7%	
Income tax expense	20.4	53.3%	18.8	16.4%	22.2	12.9%
Profit for the period	46.4	46.2%	34.6	10.4%	59.2	19.8%
Ratio to Sales	15.7%		11.6%		16.5%	

3. Segment Information by Region

bilion yen

		FY14					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Sales		295.2	9.5%	299.3	9.0%	358.3	10.5%
	Japan	112.8	-9.5%	124.4	-4.1%	151.4	-2.8%
	Ratio to Sales	38.2%		41.6%		42.2%	
	Americas	83.8	21.9%	84.2	18.9%	100.3	29.1%
	Ratio to Sales	28.4%		28.1%		28.0%	
	Europe	82.4	32.9%	74.1	23.4%	86.8	15.0%
	Ratio to Sales	27.9%		24.7%		24.2%	
	Asia and Oceania	16.1	15.1%	16.7	19.0%	19.8	29.9%
	Ratio to Sales	5.4%		5.6%		5.5%	

- Calculated according to locations of sellers.

- Europe: Including Middle and East and Africa

4. Depreciation/Amortisation

bilion yen

		FY14					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Depreciation(Tangible)							
	Consolidated	5.3	-7.1%	5.6	-0.8%	5.1	-14.7%
Amortisation(Intangible) *							
	Consolidated	10.2	1.8%	10.4	1.7%	11.5	10.7%

* Amortisation(Intangible): Including amortisation of software, etc.

5. Sales of major products

1)Sales of global products

bilion yen

	FY14					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Prograf	47.0	6.6%	48.1	6.5%	52.6	9.7%
Sales by Astellas	46.2	7.6%	47.3	8.0%	51.9	10.2%
Japan (Including Graceptor)	11.4	-8.9%	12.2	-4.2%	13.6	-1.5%
Americas	8.8	22.1%	8.1	6.3%	8.7	3.4%
Europe	18.6	9.2%	19.7	12.8%	21.0	14.3%
Advagraf	6.6	18.8%	7.3	25.6%	7.8	23.6%
Asia and Oceania	7.3	20.5%	7.2	22.5%	8.5	32.4%
Exports to third parties	0.9	-29.2%	0.9	-39.1%	0.8	-15.7%
Harnal	13.7	-10.2%	13.7	-3.3%	15.5	-8.4%
Sales by Astellas	12.5	-10.2%	13.0	-1.1%	14.6	-6.8%
Japan	3.9	-24.3%	3.9	-25.5%	4.0	-29.0%
Europe	4.5	-10.5%	4.6	8.7%	5.7	-2.4%
Asia and Oceania	4.0	11.5%	4.4	25.0%	4.8	15.5%
Bulk and Royalties	1.2	-9.6%	0.6	-33.8%	0.9	-27.7%
Vesicare	33.0	4.4%	33.6	6.3%	37.6	1.1%
Japan	5.3	-25.0%	6.5	-5.9%	7.5	-8.9%
Americas	15.5	15.6%	15.0	6.2%	17.2	3.3%
Europe	11.0	8.3%	10.4	12.1%	11.5	2.5%
Asia and Oceania	1.2	22.6%	1.2	20.8%	1.4	37.8%
Betanis/Myrbetriq/BETMIGA	10.7	128.2%	11.6	95.9%	15.4	82.7%
Japan	2.7	12.2%	3.4	41.2%	4.4	37.7%
Americas	6.2	187.3%	6.0	85.2%	7.7	72.3%
Europe	1.8	-	2.2	679.9%	3.2	340.2%
Funguard/MYCAMINE	8.9	6.7%	9.6	3.5%	11.4	12.7%
Japan	2.5	-10.2%	3.2	-0.7%	3.6	-3.2%
Americas	2.8	0.7%	2.8	-9.8%	3.5	13.1%
Europe	2.7	34.0%	2.4	16.0%	3.1	30.2%
Asia and Oceania	0.9	21.1%	1.1	39.5%	1.1	32.7%
Protopic	6.0	-1.2%	6.0	2.0%	5.9	-13.0%
Americas	3.1	8.6%	3.4	19.0%	3.2	-11.0%
Europe	2.1	29.5%	1.7	18.4%	1.9	6.9%
Asia and Oceania	0.8	14.1%	0.9	25.7%	0.9	61.0%
XTANDI	23.4	174.6%	31.3	160.1%	40.3	147.9%
US	14.7	80.4%	18.8	75.4%	25.8	104.4%
ex-US	8.7	-	12.4	866.4%	14.5	299.8%
Japan	1.5	-	4.1	-	4.6	-
Americas (ex-US)	0.4	-	0.5	322.9%	1.0	157.3%
Europe	6.7	-	7.8	567.4%	8.7	168.6%
Asia and Oceania	0.0	-	0.1	-	0.2	-
Eligard	5.1	9.5%	4.4	3.8%	5.1	8.4%
Europe	5.1	9.4%	4.4	3.6%	5.1	8.2%
Asia and Oceania	0.0	-	0.0	-	0.0	130.9%

- Sales of products in Japan are shown in a gross sales basis.
- Europe: Including Middle and East and Africa

2)Sales of products in Japan

bilion yen

	FY14					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
<Global products>	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Prograf （Including Graceptor）	11.4	-8.9%	12.2	-4.2%	13.6	-1.5%
Harnal	3.9	-24.3%	3.9	-25.5%	4.0	-29.0%
Vesicare	5.3	-25.0%	6.5	-5.9%	7.5	-8.9%
Betanis	2.7	12.2%	3.4	41.2%	4.4	37.7%
Funguard	2.5	-10.2%	3.2	-0.7%	3.6	-3.2%
XTANDI	1.5	-	4.1	-	4.6	-
<Local products in Japan>						
Lipitor [Family]	12.1	-22.8%	12.4	-24.3%	12.5	-28.3%
Caduet	2.6	-0.6%	2.6	-2.4%	2.8	-6.6%
Micardis [Family]	23.3	-1.6%	23.8	0.6%	28.0	-1.0%
Micombi	2.7	-6.8%	2.7	-7.0%	3.0	-9.8%
Micamlo	5.7	6.1%	5.8	21.8%	6.9	14.1%
Gaster	4.8	-27.5%	4.7	-29.9%	4.7	-33.5%
Myslee	4.8	-30.8%	5.0	-32.2%	5.2	-30.8%
Seroquel	3.4	-34.7%	3.2	-37.5%	3.4	-36.4%
Vaccines	5.3	10.1%	7.3	26.6%	20.9	12.4%
Cefzon	1.2	-18.9%	1.3	-21.9%	1.4	-19.1%
Celecox	8.4	-15.7%	11.3	5.2%	12.0	2.9%
Geninax	2.3	-20.9%	2.0	-0.3%	3.8	-14.2%
Bonoteo	2.6	-14.9%	3.4	1.1%	3.7	-2.6%
Symbicort	6.2	-17.5%	8.3	8.3%	10.5	0.0%
Argamate	1.5	-3.8%	1.5	-3.5%	1.6	1.0%
Kiklin	0.3	14.7%	0.4	18.9%	0.4	6.8%
Gonax	0.8	63.9%	0.9	48.4%	1.0	26.7%
Cimzia	1.1	95.4%	1.3	75.4%	1.4	48.8%
Suglat	2.5	-	0.1	-	0.7	-
Total Rx Sales In Japanese market	109.0	-9.9%	120.5	-4.3%	145.8	-4.3%

- Sales of products in Japan are shown in a gross sales basis.

3)Sales of products in Americas and Europe

bilion yen

	FY14					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Scan* (Americas)	16.6	-3.0%	15.6	-2.0%	17.1	13.8%
Lexiscan	16.5	4.6%	15.6	6.0%	17.0	16.2%
AmBisome (Americas)	1.9	-1.9%	2.3	5.0%	2.4	4.8%
Tarceva	13.6	11.6%	11.2	4.0%	12.2	12.2%
(US)	9.6	18.8%	7.6	9.2%	8.1	22.8%
(ex-US)	3.9	-2.7%	3.6	-5.7%	4.1	-4.0%
Qutenza (Europe)	0.4	35.3%	0.4	31.2%	0.5	36.1%
DIFICLIR (Europe)	0.5	92.9%	0.5	60.3%	0.5	44.3%

* Adenoscan + Lexiscan

4)Sales in Americas and Europe(Local currency)

Unit:M$

Americas	FY14 APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Net Sales	821	17.8%	810	13.2%	880	13.7%
Prograf	86	18.1%	78	1.1%	75	-9.9%
Scan*	163	-6.2%	150	-6.7%	149	-0.4%
Lexiscan	161	1.1%	150	0.8%	148	1.7%
AmBisome	19	-5.2%	22	0.1%	21	-8.0%
Protopic	31	5.0%	32	13.3%	27	-22.8%
VESIcare	152	11.8%	145	1.0%	151	-9.5%
Myrbetriq	60	177.7%	58	76.2%	68	51.9%
MYCAMINE	28	-2.7%	27	-14.2%	31	-0.1%
Tarceva	133	7.9%	107	-1.2%	106	-2.4%
US	94	14.8%	73	3.7%	70	6.5%
ex-US	38	-6.0%	34	-10.3%	36	-15.9%
XTANDI	148	79.2%	187	70.0%	239	83.9%
US	144	74.4%	181	67.2%	230	82.5%
Americas (ex-US)	4	-	5	303.1%	9	131.3%

* Adenoscan + Lexiscan

Unit:M€

Europe	FY14 APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Net Sales	589	22.3%	538	17.5%	608	9.5%
Harnal (Omnic)	41	-17.4%	38	-3.8%	46	-11.2%
Sales by Astellas	32	-17.6%	33	3.5%	40	-7.0%
Capsule	16	-10.6%	17	13.1%	20	-12.6%
OCAS	16	-23.4%	17	-4.6%	19	-0.2%
Bulk and Royalties	9	-16.8%	5	-36.4%	6	-31.1%
Prograf	139	-1.8%	149	3.9%	153	8.0%
Sales by Astellas	133	0.5%	143	7.2%	147	9.3%
Advagraf	47	9.4%	53	19.3%	55	18.0%
Exports to third parties	6	-34.2%	6	-38.7%	5	-18.5%
Vesicare	78	-0.3%	76	6.8%	80	-2.3%
BETMIGA	13	-	16	638.2%	23	313.9%
Protopic	15	19.2%	13	12.9%	13	1.8%
MYCAMINE	19	23.4%	18	10.4%	22	24.3%
Eligard	36	0.7%	32	-1.3%	36	3.4%
Qutenza	3	24.5%	3	27.4%	4	30.8%
DIFICLIR	3	77.6%	4	54.7%	4	38.1%
XTANDI	48	-	56	530.6%	61	151.0%

- Europe: Including Middle and East and Africa

R&D Pipeline (February 2015)

1. Global Development

(1) Approved

#Compounds with "In-house" in this column include one discovered by collaborative research. (The same applicable hereafter.)

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor#	Remarks
MDV3100 enzalutamide	XTANDI (Dec. 2014)	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy in whom chemotherapy is not yet clinically indicated	Europe	Oral	Medivation	New indication

(2) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
erlotinib	HER1/EGFR tyrosine kinase inhibitor	Pediatric ependymoma	US	Oral	In-house (co-development with Roche/ Genentech)	Pediatric ependymoma is not a new indication, rather a supplement submitted to the FDA to fulfill Pediatric Written Request.

(3) Phase-lll / Phase-ll (1/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Non-metastatic castration-resistant prostate cancer, Prostate cancer in patients with non-metastatic biochemical recurrence	US/Europe/Asia Phase-III	Oral	Medivation	New indication
		Breast cancer	US/Europe Phase-II			New indication
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	US/Europe/Japan Phase-III	Injection	Vical	
		Cytomegalovirus infection or reactivation in solid organ transplant recipients	US/Europe Phase-II			
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	US/Europe Phase-III	Oral	In-house	New indication (pediatric)
EB178 solifenacin/ mirabegron	Concomitant use of solifenacin and mirabegron	Urinary frequency, urinary incontinence or urgency associated with overactive bladder	Europe/US/Asia Phase-III	Oral	In-house	

(3) Phase-lll / Phase-ll (2/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	Japan Phase-III	Oral	Cubist	
		Clostridium difficile infection in pediatric patients	Europe Phase-III			New indication (pediatric)
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan Phase-III US/Europe Phase-II*	Oral	In-house	
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	Europe Phase-III Japan Phase-II	Oral	FibroGen	
YM311 (FG-2216)	HIF stabilizer	Renal anemia	Europe Phase-II Japan Phase-I	Oral	FibroGen	
ASKP1240	Anti-CD40 monoclonal antibody	Prevention of organ transplant rejection	US Phase-II Japan Phase-I	Injection	Kyowa Hakko Kirin	
ASP1707	GnRH antagonist	Endometriosis	Europe/Japan Phase-II	Oral	In-house	
		Prostate cancer	Europe Phase-I			

*Janssen Biotech, Inc. has exercised its right to terminate the license agreement to develop and commercialize ASP015K outside Japan.

(3) Phase-lll / Phase-ll (3/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP8477	Inhibition of central sensitization	Neuropathic pain	Europe Phase-II	Oral	In-house	
ASP8232	VAP-1 inhibitor	Diabetic nephropathy	Europe Phase-II	Oral	In-house	
		Diabetic macular edema	US Phase-II			
ASP8273	Mutant-selective irreversible EGFR inhibitor	Non-small cell lung cancer	Japan Phase-II US Phase I	Oral	In-house	

2. Local Development: Japan

(1) Approved

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
nitisinone	Orfadin (Dec. 2014)	4-Hydroxyphenyl pyruvate dioxygenase inhibitor	Hereditary tyrosinemia type 1	Japan	oral	Sobi	

(2) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP7374	Influenza vaccine	Prophylaxis of seasonal influenza	Japan Filed (May 2014)	Injection	UMN Pharma	
certolizumab pegol	PEGylated anti-tumor necrosis factor-alpha antibody	Disease modifying anti-rheumatic drugs (DMARD)-naive rheumatoid arthritis	Japan Filed (Jun. 2014)	Injection	UCB	New indication
nateglinide	Fast acting insulin secretion enhancer	Type 2 diabetes Combination with DPP-4 inhibitor	Japan Filed (Jul. 2014)	Oral	Ajinomoto Pharmaceuticals	New indication
YM060 ramosetron	5-HT3 receptor antagonist	Irritable bowel syndrome with diarrhea in female patients	Japan Filed (Jul. 2014)	Oral	In-house	New indication

(3) Phase-lll / Phase-ll (1/2)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
YM533 beraprost sodium	Prostacyclin receptor stimulator	Chronic renal failure (primary, nephrosclerosis)	Japan/Asia Phase-III	Oral	Toray	New indication
FK949E quetiapine	Serotonin/dopamine antagonist	Depressive episode in bipolar disorders	Japan Phase-III	Oral	AstraZeneca	New indication New formulation
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients not on dialysis with chronic kidney disease	Japan Phase-III	Oral	Amgen	New indication
		Hyperphosphatemia in patients on dialysis with chronic kidney disease (granule formulation)	Japan Bioequivalence study	Oral		New formulation
ASP3550 degarelix	GnRH antagonist	Prostate cancer (three-month formulation)	Japan Phase-III	Injection	Ferring	New formulation
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
AMG 145 evolocumab	Anti-PCSK-9 monoclonal antibody	Hyperlipidemia	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
AMG 102 rilotumumab	Anti-HGF monoclonal antibody	Gastric cancer	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	

(3) Phase-lll / Phase-ll (2/2)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP0456 linaclotide	Guanylate cyclase type-C receptor agonist	Irritable bowel syndrome with constipation	Japan Phase-III	Oral	Ironwood	
		Chronic constipation	Japan Phase-II			
ASP7373	Influenza vaccine	Prophylaxis of H5N1 influenza	Japan Phase-II	Injection	UMN Pharma	
ASP7991	Calcium-sensing receptor activator	Secondary hyperparathyroidism	Japan Phase-II	Oral	In-house	
AMG 337	MET inhibitor	Gastric cancer	Japan Phase-II	Oral	Amgen (co-development with Amgen Astellas)	

3. Local Development: Europe

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
NGX-4010 capsaicin	TRPV1 agonist	Peripheral diabetic neuropathy	Europe Filed (Dec. 2014)	Patch	HealthCare Royalty Partners	New indication

4. Local Development: US

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
isavuconazonium	Azole antifungal	Invasive aspergillosis and invasive mucormycosis	US Filed (Jul. 2014)	Injection Oral	Basilea	
		Candidemia / Invasive candidiasis	US Phase-III			New indication

5. Phase-I

Code No. Generic Name	Target Disease	Dosage Form	Licensor
AGS-16C3F	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASG-22ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP9226	Neuropathic pain	Oral	In-house
ASP3662	Alzheimer's disease	Oral	In-house
ASG-15ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP2215	Cancer	Oral	In-house
ASP3325	Hyperphosphatemia	Oral	In-house
CK-2127107	Skeletal muscle disease	Oral	Cytokinetics
ASP5878	Cancer	Oral	In-house
ASP7962	Osteoarthritis, Chronic low back pain	Oral	In-house
YM178 mirabegron	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	Oral	In-house
ASP7657	Diabetic nephropathy	Oral	In-house
ASP3700	Osteoarthritis	Oral	In-house
AGS67E	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASP5633	Stress urinary incontinence	Oral	In-house
ASP2205	Stress urinary incontinence	Oral	In-house
ASP5094	Rheumatoid arthritis	Injection	In-house
ASP6858	Chronic kidney disease	Oral	In-house

6. Project Discontinued

Code No. Generic Name	Target Disease	Area / Phase	Reason
ASP4901 (AKP-002)	Lower urinary tract symptoms associated with benign prostatic hyperplasia	Japan Phase-II	Development was discontinued because the Phase-II study did not demonstrate the expected efficacy.

<Changes from the Previous Announcement on October 31, 2014> (Changed underlined items)

Approval / Labeling revision

-Enzalutamide: Deleted the following description.

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
MDV3100 enzalutamide	XTANDI (Sep. 2014)	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer*1	US	Oral	Medivation	
	XTANDI (Labeling revision in Oct. 2014)		Castration-resistant prostate cancer*2	Japan			

*1 Indication expanded for metastatic castration-resistant prostate cancer to include patients who have not yet received chemotherapy.

*2 Following description was removed in the precautions for indications; the efficacy and safety of the drug have not been established in patients with prostate cancer who have not received chemotherapy.

-Enzalutamide: Approved in Europe in Dec. 2014.

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
MDV3100 enzalutamide	XTANDI (Dec. 2014)	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy in whom chemotherapy is not yet clinically indicated	Europe	Oral	Medivation	New indication

-Nitisinone: Approved in Japan in Dec. 2014.

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
nitisinone	Orfadin (Dec. 2014)	4-Hydroxyphenyl pyruvate dioxygenase inhibitor	Hereditary tyrosinemia type 1	Japan	oral	Sobi	

Filed

-Capsaicin: Filed in Europe in Dec. 2014. License agreement was suceeded from NeurogesX to HealthCare Royalty Partners.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
NGX-4010 capsaicin	TRPV1 agonist	Peripheral diabetic neuropathy	Europe Filed (Dec. 2014)	Patch	HealthCare Royalty Partners	New indication

-Isavuconazoium: Updated the generic name from isavuconazole.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
isavuconazonium	Azole antifungal	Invasive aspergillosis and invasive mucormycosis	US Filed (Jul. 2014)	Injection Oral	Basilea	
		Candidemia / Invasive candidiasis	US Phase-III			New indication

Phase-III / Phase-II

-ASP015K: Changed the description of footnote.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan Phase-III US/Europe Phase-II*	Oral	In-house	

*Janssen Biotech, Inc. has exercised its right to terminate the license agreement to develop and commercialize ASP015K outside Japan.

-ASP8273: Entered into Phase-II.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP8273	Mutant-selective irreversible EGFR inhibitor	Non-small cell lung cancer	Japan Phase-II US Phase I	Oral	In-house	

-AMG 337: Entered into Phase-II.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
AMG 337	MET inhibitor	Gastric cancer	Japan Phase-II	Oral	Amgen (co-development with Amgen Astellas)	

Phase-I

-AGS-16C3F: Updated the Code No. from "AGS-16M8F/AGS-16C3F" to "AGS-16C3F".

-CK-2127107 [Skeletal muscle disease]: Updated the target disease deleting the description of non-neuromuscular indications.

-ASP2205 [Stress urinary incontinence]: Entered into Phase-I.

-ASP5094 [Rheumatoid arthritis]: Entered into Phase-I.

-ASP6858 [Chronic kidney disease]: Entered into Phase-I.

Project Discontinued

-ASP4901 (AKP-002) [Lower urinary tract symptoms associated with benign prostatic hyperplasia] in Phase-II in Japan: Discontinued the development.